Standard methods for determining dose per monitor unit values in a patient do not yet exist for proton therapy. Indeed, some aspects of D/MU estimation remain poorly understood, such as the conversion of absorbed dose in a water phantom to absorbed dose in a patient. This study focused on the water-to-patient absorbed dose conversion factor, FCSPS, which accounts for differences in scatter (from the range compensator and internal patient anatomy) between patient treatments and their corresponding calibration irradiation in a homogeneous waterbox-phantom. We estimated FCSPS for 32 prostate fields using a pencil beam dose algorithm in the treatment planning system (TPS). The mean FCSPS value was 1.006; its standard deviation of the mean was ±0.001. The lower bound for uncertainty in FCSPS, μFCSPS, was estimated for a subset of fields through comparisons of TPS dose predictions with measurements and Monte Carlo (MC) simulations. Comparison of TPS predictions and measurements yielded μFCSPS of 0.4% -0.8%. Comparison of TPS predictions and MC simulations yielded μFCSPS < 0.3%. For a prostate treatment, a comparison of FCSPS values from TPS predictions with the historical value of 1.0 yielded μFCSPS < 3% and a mean μFCSPS of 0.6%. Regardless of estimation method, μFCSPS was approximately 1%, suggesting that uncertainty in FCSPS for proton treatments of prostate cancer is clinically acceptable.
. Still, in contrast to photon and electron therapy, to date, a protocol to harmonize methods for estimating absorbed dose from proton therapy in a patient is lacking.
Nonetheless, progress is being made toward a more complete understanding of the determination of absorbed dose in a patient receiving proton therapy. 22- 31 Specifically, progress includes the creation of a geometrical framework and an initial estimate of 1.0 for a water-to-patient absorbed dose conversion factor 22 as well as validation of Monte Carlo (MC)-simulated D/MU data within 1 to 1.5% of measured data 25,27, 29, 31 . In addition, studies by Fontenot et al. 26 , Akagi et al. 24 , and Titt et al. 28 indicate that absorption and scatter of the treatment beam in fieldspecific collimation devices, range compensators (RC), and patient anatomy have the potential to increase uncertainty in estimates of absorbed dose per monitor unit in the patient, (D/MU)p, by 1% or more. In this respect, Akagi et al. 24 demonstrated that the combined effects of scatter in the RC, scatter in the patient, and scatter from the patientspecific collimator could yield (D/MU)p values 2% to 3% higher or lower than those measured in a phantom. These results were confounded by field-size effects, which were subsequently addressed by Titt et al. 28 Finally, Fontenot et al. 26 addressed uncertainty in D/MU measurements under patient-specific fields associated with the presence of the range compensator and they recommended measurement without the range compensator. Together, these works underscore the need for standard methods of determining (D/MU)p values, the potential complexities of doing so, and the need to better understand the total uncertainty in (D/MU)p.
The objective of this study was to estimate total uncertainty in (D/MU)p, values for patients who receive proton therapy for prostate cancer. In particular, we used treatment planning system (TPS) calculations, measurements, MC simulations, and a comparison to the historical value of 1.0 to quantify the least understood factor in the water-to-patient absorbed dose conversion factor, FCSPS, the multiplicative factor that takes into account scatter from the RC and internal patient scatter, and its uncertainty.
Materials and Methods

D/MU formalism
The formalism for calculating the beam output, or D/MU value, for proton therapy was based in part on previously reported methods. comprises a collimated 10 cm × 10 cm field with a range of 28.5 cm (250 MeV proton beam), a 10-cm spread-out Bragg peak (SOBP), and a center of modulation at 23.5-cm depth in water that was located at isocenter. This range corresponds to the most penetrating beam available from the treatment unit at our institution with a medium field size. Note that a water equivalent phantom, e.g., a solid plastic phantom, may also be used. For simplicity and brevity, we shall consider these as being interchangeable.
We next defined D/MU value in a water phantom as before, except the proton beam parameters were taken from a treatment field (Figure 1b) , as 
where Fi are as follows. FOF corrects for changes in beam output which result from differences in the proton beam energy spectrum relative to the reference condition; these changes are due to differences in the properties of the beam that is injected into the treatment head and due to scatter and absorption in the range modulator wheel. FRS corrects for changes in beam output due to the range shifter. FSOBP corrects for changes in the beam output due to differences in the SOBP relative to the reference field. FInvSq corrects for changes in beam output which result from differences in beam divergence relative to the reference condition; changes in beam divergence occur when there are changes in the distance from the effective source to the field specific point of measurement, or calibration point. (The calibration point for the reference condition was located at isocenter; the distance from the effective source to isocenter for our passively scattered beamlines was 270 cm.) FFS corrects beam output for differences in proton fluence due to changes in the uncollimated field size (i.e., the amount of lateral beam spreading), and FColS corrects beam output for differences in scatter from the reference aperture (10 cm x 10 cm) to the patient-specific aperture. 28 We defined the (D/MU) value in the patient ( Figure 1c ) according to
where, Fp,w is a conversion factor that accounts for differences in the D/MU values between the field-specific calibration condition in water and the patient-specific treatment condition in tissue, or
FMS corrects for effect of differences in the proton mass stopping power in tissue relative to that in water. It can be determined using MC simulations or analytical calculations. 33, 34 The compensator scatter and patient scatter factor, FCSPS, takes into account differences in the beam output due to differences in the scattering and attenuation within the patient and RC together relative to that of a water box phantom and no RC.
FCSPS was the focus of our study and we considered two methods for estimating it. In the first method, which we shall refer to as the treatment planning system method (TPS method), we define in equation (7) is the absorbed dose per MU in water (or water equivalent material) at the calibration point with the RC in the field, and the other terms in equations (7) and (8) are as defined for equation (5) . The calibration point is the location where the relative absorbed dose (in MU) is calibrated to the prescribed absolute absorbed dose (in Gy). It typically corresponds to a region in the patient or phantom that will receive uniform dose and is close to the center of the SOBP. Because the prostate treatment plans used in this work were isocentric, all treatment fields within a plan shared the same calibration point, i.e., isocenter (IEC 1989). As such, the calibration point for each individual treatment field occupied the same point in space, whether in water or in the patient.
Uncertainty budget
We used an uncertainty budget for (D/MU)p as an a priori guide in studying the numerical impact of uncertainty in various factors on uncertainty in (D/MU)p. Specifically, we prepared a lookup table (see Table 1 ) to determine which intervals of uncertainty in (D/MU)w, FColS, and FCSPS, respectively, would cause ≤ 5% uncertainty in (D/MU)p. In it, we considered three methods for determining (D/MU)p. The main difference between methods was the way in which (D/MU)w was determined, i.e., through use of a TPS, measurements, or MC simulations. (9) to (11 When using a TPS to predict (D/MU)w, we have
where,   We used standard methods for error propagation to estimate the relative uncertainty in (D/MU)p as,
where, μ was the symbol used to represent uncertainty. Each quantity in equations (9) through (11) has an associated uncertainty, and several of those uncertainties were variable or unknown. Thus, the estimation of relative uncertainty in (D/MU)p (Table 1) was based on a combination of three methods, including standard propagation of errors 36 , use of uncertainty values from the literature, and sensitivity testing to quantify the impact of contributing uncertainties that were not available from the literature or that were not determined in this work. found to be uncorrelated, and intervals of each factor were found that satisfied the 5% uncertainty criterion of (D/MU)p. Values of μ(D/MU)w were restricted to the interval from 2.5% to 4.5%, μFColS was set to 1.0%, as was μFMS, and μFCSPS were restricted from 1.5% to 4.5%. In other words, the results of the a priori estimates of relative uncertainty in (D/MU)p (Table 1) Therefore, an interval of (D/MU)w values was provided. This interval takes into account reported differences between the ICRU and IAEA protocols. 38,39, 40 Consequently, the interval of values used to estimate the relative uncertainty in (D/MU)w was ±2.5% to ±4.5%.
Parameter values used to populate the uncertainty budget
The value used for FColS, 1.02, reflects the importance of the collimator in proton beam dosimetry. 28 The uncertainty for FColS, μFColS, was estimated using an interval of ±1%, which accounted for deviations in the treatment field from a 10 cm x 10 cm collimated field size, variation in beam energies from 160 MeV to 250 MeV, and variation in the location of the calibration point relative to the center of the SOBP.
The value used for FMS, 1.0, is an estimate of the dosimetric effect that a medium other than water causes due to differences in the proton mass stopping powers. The uncertainty in FMS, μFMS, was estimated at 1% using mass stopping power ratios 41 of water to muscle. 24 Titt et al. 28 reported a 2% effect for general dosimetric accuracy and a 2.5% -3% effect for the collimator size, energy, and SOBP used in this study, so uncertainty of ±1% was used to account for this.
FMS
1.00 (1.00 -1.02) ±1% Siebers et al. 33 , Paganetti 34 Siebers et al. 33 reported a water-to-ICRU tissue mass stopping power factor of 1.01, which differed from water-to-cortical bone or -lung by approx. 10% or 2%, respectively. 24 Parameter values and uncertainties were measured in phantom, then manually corrected for collimator scatter. ±3.6% Akagi et al. 24 Parameter values and uncertainties were measured in phantom, then manually corrected for collimator scatter.
1.00 ≈±4% Sahoo et al. 30 Sahoo et al. 30 30 An average of FCSPS values from the previous rows, i.e., values estimated from data reported by Akagi et al. 24 and Sahoo et al. 30 .
The values for FCS and FCSPS were determined using data from the only publications which directly addressed patient and compensator scatter. 24 and Sahoo et al. 30 , yielding the FCSPS value of 1.03 listed in Table 2 . The uncertainty in our estimate of FCSPS in Table 2 was unknown, thus determining a value of μ(FCSPS) was a central focus of this work (section 2.5) as it is needed for the estimation of uncertainty in (D/MU)p.
Estimation of FCSPS for prostate treatment fields
Estimation of FCSPS using the TPS method
The TPS method (eq. 5) was applied to each of 32 prostate treatment fields taken from a representative sample of patients (n = 16, 2 treatment fields each) from our practice. Patients were selected using the consecutive sampling method 42 to minimize selection bias and indexed as 1 through 16. Patients in this study (1) 43 Briefly, in all fields, the calibration point location remained fixed at isocenter (Figure 2 ) to minimize the dosimetric impact of differences in beam divergence. Also, as described by Newhauser 22 , the water-equivalent depth of the calibration point was made equal for a treatment plan and the corresponding verification plan by shifting the water phantom in the verification plan. By maintaining the same location and water-equivalent depth of the calibration point in the patient and water phantom, dosimetric differences due to differences in scatter in the patient and phantom were isolated, so their respective effects on dose delivered to the calibration point could be revealed. 
Figure 2: Dose distributions (shown by color wash) differ between the patient and water. A right lateral prostate treatment field (A). The verification plan feature in the treatment planning system was used to apply the same treatment field to water with the range compensator not included (B) and included (C). Additionally, the position of the downstream face of the water phantom is shown relative to the patient's downstream surface in the treatment field (A) and the verification fields for the case when the range compensator is not in the beam path (B) and the case when the range compensator is in the beam path (C). When the range compensator is not present, the Z-position of the downstream face of the water phantom is given by
x R Z    270 B ,
where x refers to the compensator thickness and R refers to the water-equivalent range to the calibration point, Zcal, ( blue 'X') in the treatment field along the axis of measurement. Similarly, when the range compensator is present, the Z-position of the water phantom is given by
R Z   270 C .
Table 3: Summary of parameters for patients 17 and 18. Measurement point (MP) depth describes the water-equivalent depth of the calibration point from the phantom surface. This value is given both without the range compensator (no RC) in place and with it (RC). "Air gap" describes the distance between the downstream face of the treatment snout to the upstream face of the phantom. The modulator wheel identification (ID), the spread-out Bragg peak (SOBP) width, the beam energy, and penetration range were specified for each field based on the treatment plan. The penetration range and modulated width of each field are reported in water-equivalent thickness (WET
Estimation of FCSPS using the TPS+M method
The TPS-plus-measurement (TPS+M) method used a combination of measurements of absorbed dose in a water phantom and TPS calculations to estimate FCSPS according to equation (6) . This method was applied to four treatment fields from two patients. These patients met the same inclusion criteria as patients 1 to 16 except they were selected prospectively so that we were able to make the additional measurements required for this method. The corresponding patient indices were 17 and 18 (Table 3) .
Estimation of FCS using measurements
Our measurements of FCS, using equation (7) , the water-equivalent thickness of the phantom was increased to preserve a fixed location of the calibration point. Finally, FCS was estimated according to equation (7).
Estimation of FPS using the TPS
The second step in generating FCSPS values with the TPS+M method was to determine FPS using equation (8) . Because in vivo measurements were not feasible, the PBA in the TPS was used to determine the ratio of absorbed dose at the calibration point in the patient, 
Uncertainties in FCSPS
Estimation of uncertainty in FCSPS from the TPS method
When FCSPS was determined using the TPS method, i.e., TPS dose estimates applied to equation (5) 
where, DTPS represents absorbed dose from the TPS method at the calibration point in the patient, and DMC represents absorbed dose from MC simulations at the calibration point in the patient.
In practice, we used differences in dose profiles to estimate DTPS and DMC for patients 17 and 18. These profiles were generated using the PBA 35 in the TPS and the Monte Carlo Proton Radiotherapy Treatment Planning (MCPRTP) code 44, 45 . In general, Contemporary proton PBAs in the TPS system provide excellent accuracy 44 , especially in homogeneous media, superior to that of broad beam algorithms in heterogeneous media. The improvement in accuracy comes mostly at the cost of greater computation times. Because of inherent approximations in the PBA, it may not provide sufficient accuracy in extremely heterogeneous media, at material and/or density interfaces, or in other complex situations. The MCPRTP used the Monte Carlo N-particle eXtended radiation transport code 46 with parallel processing as a radiation dose calculation engine. Each component of the proton treatment unit was modeled in detail and patient's CT images were converted to voxelized phantom in the MCNPX code. The accuracy of the Monte Carlo simulation model has been previously evaluated by Titt et al. 47 More details of Monte Carlo simulations can be found in previous reports from our group. 44, 48, 49, 50
DMC was considered to provide the best estimate of the true absorbed dose at the calibration point. This distinction was made for two reasons.
(1) The MC simulation model used more complete and realistic physics models to describe multiple coulomb scattering and nuclear interactions. 27 (2) The MC simulations took into account the variations in elemental composition and mass density of various tissues, whereas the TPS approximated all tissues as water of varying density. 45 Input data to both algorithms (i.e., the CT data set, aperture, RC, and beam line parameters) were identical, so differences in predicted dose distributions were attributed solely to differences in the pencil beam and Monte Carlo dose algorithms.
Estimation of uncertainty in FCSPS from the TPS+M method
When FCSPS was determined using the TPS+M method, i.e., TPS dose estimates and measurements (section 2.4.2), the
, was estimated using a statistical approach: differences between FCSPS values generated with the TPS+M and TPS methods were used to estimate upper and lower bounds of
The lower bound of the absolute uncertainty in
where, . Mean values were used because it was assumed that most random variations in the data would be averaged out of the respective data sets, so the resulting difference would represent a clinically representative estimate of the differences between calculation methods, i.e., a lower bound for the true uncertainty in FCSPS. (15) where, the subscripts xi indicate that the TPS and TPS+M calculations were performed for each individual field in the sample, i.e., patients 17 and 18 (see section 2. Table 4 reveals good agreement between values of FCSPS calculated with the TPS method and those calculated with the TPS+M method. The standard deviation in FCSPS for the TPS method was smaller than the corresponding value from the TPS+M method. Also, there was a larger interval in values for the TPS+M method than for the TPS method. There are several possible explanations for this. One is that additional statistical uncertainty was introduced by the measurements. Another is that the measurements better indicate the true standard deviation, while the TPS method artificially smooths out some of the true variation.
Results
Estimation of FCSPS using the TPS method
Estimation of FCSPS using the TPS+M method
Estimation of uncertainty in FCSPS
Uncertainty in FCSPS using the TPS method
Absorbed dose predictions from MC and pencil beam algorithms were compared for a prostate treatment in one of the patients (patient 17) following the methods of 2.5.1. Differences in estimates of absorbed dose between MC simulations and the TPS method resulted in a 10.5 cGy difference between profiles at isocenter for the right lateral field and a 4.7 cGy difference for the left lateral field. The absorbed doses from the right and left lateral fields for the treatment plan at isocenter, which were used to represent Dw as an approximation, were 3550 cGy and 3570 cGy, respectively. Therefore, the   TPS CSPS F  was less than 0.3% for the individual fields. These estimates suggest that the contribution of μFCSPS to uncertainty in (D/MU)p for this particular patient was negligible. 
Uncertainty in FCSPS using the historical estimate
Estimates of FCSPS done using the TPS method were compared to the historical value of 1.0 for FCSPS. Descriptive statistics for this analysis are listed in Table 5 . 
Discussion
We estimated uncertainty in (D/MU)p for patients receiving proton therapy for cancer of the prostate. In particular, we compared estimates of uncertainty in FCSPS by means of measurements, MC simulations, and pencil beam dose calculations. Our results confirm that when FCSPS is included in the estimation of (D/MU)p,, the uncertainty in (D/MU)p is less than 5%, regardless of the method used to calculate FCSPS.
Our findings on FCSPS are similar to those of Newhauser 22, 51 and Sahoo et al. 30 At the outset of this work, the standard of care at our institution followed the approach described by Newhauser 22 in which FCSPS was taken as unity. Subsequently Newhauser et al. 51 reported that FCSPS for prostate treatment fields was near the historical value of 1.0 based on results of a phantom study. Likewise, Sahoo et al. 30 reported that FCSPS spanned the interval 0.957 to 1.089 with a mean value of 1.00 ± 0.04. However, we note that Sahoo et al. 30 did not specify which anatomical treatment sites these values were from. Therefore, it is difficult to make a direct comparison of those results with the findings from this work.
As noted in section 2.3, we found no directly comparable reports on μFCSPS in the literature for prostate treatment. Our findings on μFCSPS differ from those in the works most similar to ours, that is, reports from Akagi et al. 24 and Sahoo et al. 30 . Akagi et al. 24 reported a relative uncertainty of 3.6% in the measured value of FCSPS; this value exceeds ours by approximately a factor of 10. However, the uncertainty reported by Akagi et al. 24 took into account the errors in reproducing collimator scatter (FColS) and inaccuracy in analytical modeling of patient anatomy which were not applicable to our study.
One of the clinical implications of this work is that accuracy of (D/MU)p values, in the special case of prostate treatment fields, does not depend strongly on accurate knowledge of the FCSPS factor. Thus, this work also provides an evidential basis and rationale for standardizing absolute proton dosimetry, which is a key requisite step to conduct multi-institution clinical trials.
This study had several limitations. First, it considered normal patient anatomy, e.g., the effects of implanted fiducial markers, hip prostheses, and organ motion on (D/MU)p and its uncertainty were not included. However, these are not serious limitations because solutions for fiducial markers are known 52,53,54,55 , and although hip prostheses are relatively rare, there are MV/kV imaging solutions that are available to correct for their effects 56 . Second, we considered only the lateral opposed-pair treatment technique, while involvement of pelvic lymph nodes or treatment of other more complex treatment strategies 57,58 would require a much different application of our present findings. Third, our findings are specific to the treatment planning and delivery systems in use at our institution for a passively scattered treatment; there may be additional differences between this study and other treatment techniques, such as intensity-modulated proton therapy. Nonetheless, the methods and results of this study may serve as a qualitative guide for similar studies of other proton therapy systems.
Given the complexities and uncertainties associated with estimation of absorbed dose in the patient, additional studies are needed to test whether the findings of this work will hold for other anatomical sites. In our laboratory, additional studies are now under way to address estimation of uncertainties in (D/MU)p in the thorax.
Conclusion
In conclusion, our study investigated the water-to-patient absorbed dose conversion factor, FCSPS, one of the least well-understood factors in proton output calculation, and found that mean FCSPS value was 1.006 and uncertainty in FCSPS was approximately 1%, suggesting that uncertainty in FCSPS for proton therapy of prostate cancer is clinically acceptable.
